Radium-223 in patients with prostate specific antigen (PSA) progression and without clinical metastases following maximal local therapy: A pilot study

CONCLUSIONS: Radium-223 in patients with PSA relapse following maximal local treatment without clinical metastases is safe. However, the clinical benefit of Ra-223 in this setting is doubtful as significant oncological benefit is lacking.PMID:34099385 | DOI:10.1016/j.urolonc.2021.04.034

Source: Urologic Oncology - June 8, 2021 Category: Urology & Nephrology Authors: Lorenzo Tosco Ga ëtan Devos Laura Schillebeeckx Steven Pans Karolien Goffin Wouter Everaerts Hendrik Van Poppel Steven Joniau Source Type: research